Anti-Fungal Agents That Are Cyp3a4 Substrates has 2 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ivosidenib, Enasidenib Mesylate. Patients taking Anti-Fungal Agents That Are Cyp3a4 Substrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 2
- Contraindicated
- 1
- Major
- 1
Contraindicated (1)
- Anti-Fungal Agents That Are Cyp3a4 Substrates + Ivosidenib— Ivosidenib induces CYP3A4, causing expected loss of antifungal efficacy. Do not administer concomitantly.
Major (1)
- Anti-Fungal Agents That Are Cyp3a4 Substrates + Enasidenib Mesylate— Do not administer enasidenib with anti-fungal agents that are CYP3A substrates due to expected loss of antifungal effica…